The Corner Booth

In the coming years, Tandem Diabetes Care has ambitious plans to introduce the next version of its tubed t:slim insulin pump, a series of three smaller devices to reduce and eventually eliminate tubes completely, and features allowing users to fully control their insulin pump and even deliver bolus insulin with their smartphones. The San Diego, California-based company revealed all of this at its first-ever R&D Day on Dec. 6, 2021, mapping out its 5-year pipeline plan for new technology. While medtech timelines often slip, given corporate priorities and the Food and Drug Administration (FDA) review process, Tandem expects that it will be able to develop and launch most — if not all — of these new products on a rolling scale between 2022 and 2027. "As a diabetes care company, we realize there is not a one-size-fits-all solution to managing this complex condition," Tandem CEO John Sheridan said. "'Positively different' is a sum total of our brand.....

It wasn't until a quarter century after being diagnosed with type 1 diabetes (T1D) that Lori Salsbury in Arkansas realized the condition she'd been living with since she was 15 years old might not be what she thought it was. Though her mom and sister were both initially misdiagnosed with type 2 diabetes (T2D) and later correctly dubbed T1Ds, Lori didn't have a reason at first to be suspicious of her own T1D diagnosis. Not until 2015, when she began seeing more people with diabetes sharing their stories online and realized something was off for her. Sure, there is a mantra in our community that "Your Diabetes May Vary." But for Salsbury, the particulars of her T1D just "didn't match" what she saw others in the D-Community sharing or what doctors and nurses described as the symptoms most newly diagnosed T1D experience. At the time of her diagnosis, Salsbury was in her mid-20s and seemed quite healthy. She didn't get nauseous or sick, e...